BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

653 related articles for article (PubMed ID: 30686354)

  • 1. [Not Available].
    Rahal I; Cabannes-Hamy A; Boissel N
    Bull Cancer; 2018 Dec; 105 Suppl 2():S158-S167. PubMed ID: 30686354
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Not Available].
    Dourthe MÉ; Yakouben K; Chaillou D; Lesprit E; Dalle JH; Baruchel A
    Bull Cancer; 2018 Dec; 105 Suppl 2():S147-S157. PubMed ID: 30686353
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Not Available].
    Salles G; Sesques P; Ferrant E; Safar V; Ghesquieres H; Bachy E
    Bull Cancer; 2018 Dec; 105 Suppl 2():S168-S177. PubMed ID: 30686355
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Not Available].
    Le Bourgeois A
    Bull Cancer; 2018 Dec; 105 Suppl 2():S188-S197. PubMed ID: 30686357
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Not Available].
    Gauthier J
    Bull Cancer; 2018 Dec; 105 Suppl 2():S214-S217. PubMed ID: 30686360
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Not Available].
    Rubio MT; Galaine J; Borg C; Daguindau É
    Bull Cancer; 2018 Dec; 105 Suppl 2():S135-S146. PubMed ID: 30686352
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Not Available].
    Chabannon C; Larghero J
    Bull Cancer; 2018 Dec; 105 Suppl 2():S198-S204. PubMed ID: 30686358
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Not Available].
    Alcazer V; Delenda C; Poirot L; Depil S
    Bull Cancer; 2018 Dec; 105 Suppl 2():S178-S187. PubMed ID: 30686356
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Not Available].
    Pinturaud M; Vasseur M; Odou P
    Bull Cancer; 2018 Dec; 105 Suppl 2():S205-S213. PubMed ID: 30686359
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Co-infusion of haplo-identical CD19-chimeric antigen receptor T cells and stem cells achieved full donor engraftment in refractory acute lymphoblastic leukemia.
    Cai B; Guo M; Wang Y; Zhang Y; Yang J; Guo Y; Dai H; Yu C; Sun Q; Qiao J; Hu K; Zuo H; Dong Z; Zhang Z; Feng M; Li B; Sun Y; Liu T; Liu Z; Wang Y; Huang Y; Yao B; Han W; Ai H
    J Hematol Oncol; 2016 Nov; 9(1):131. PubMed ID: 27887660
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CAR-T Cell Therapy for Acute Lymphoblastic Leukemia: Transforming the Treatment of Relapsed and Refractory Disease.
    Pehlivan KC; Duncan BB; Lee DW
    Curr Hematol Malig Rep; 2018 Oct; 13(5):396-406. PubMed ID: 30120708
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evidence of long-lasting anti-CD19 activity of engrafted CD19 chimeric antigen receptor-modified T cells in a phase I study targeting pediatrics with acute lymphoblastic leukemia.
    Ma F; Ho JY; Du H; Xuan F; Wu X; Wang Q; Wang L; Liu Y; Ba M; Wang Y; Luo J; Li J
    Hematol Oncol; 2019 Dec; 37(5):601-608. PubMed ID: 31465532
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The severe cytokine release syndrome in phase I trials of CD19-CAR-T cell therapy: a systematic review.
    Jin Z; Xiang R; Qing K; Li X; Zhang Y; Wang L; Zhu H; Mao Y; Xu Z; Li J
    Ann Hematol; 2018 Aug; 97(8):1327-1335. PubMed ID: 29766234
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CAR T-cells in acute lymphoblastic leukemia: Current results.
    Dourthe ME; Baruchel A
    Bull Cancer; 2021 Oct; 108(10S):S40-S54. PubMed ID: 34920807
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An analytical biomarker for treatment of patients with recurrent B-ALL after remission induced by infusion of anti-CD19 chimeric antigen receptor T (CAR-T) cells.
    Zhang Y; Zhang W; Dai H; Wang Y; Shi F; Wang C; Guo Y; Liu Y; Chen M; Feng K; Zhang Y; Liu C; Yang Q; Li S; Han W
    Sci China Life Sci; 2016 Apr; 59(4):379-85. PubMed ID: 27009300
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current Status of CAR T Cell Therapy for Leukemias.
    Harris K; LaBelle JL; Bishop MR
    Curr Treat Options Oncol; 2021 Jun; 22(7):62. PubMed ID: 34097135
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advances in the development of chimeric antigen receptor-T-cell therapy in B-cell acute lymphoblastic leukemia.
    Zhang X; Li JJ; Lu PH
    Chin Med J (Engl); 2020 Feb; 133(4):474-482. PubMed ID: 31977556
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Donor-derived CD19-targeted T cell infusion induces minimal residual disease-negative remission in relapsed B-cell acute lymphoblastic leukaemia with no response to donor lymphocyte infusions after haploidentical haematopoietic stem cell transplantation.
    Chen Y; Cheng Y; Suo P; Yan C; Wang Y; Chen Y; Han W; Xu L; Zhang X; Liu K; Chang L; Xiao L; Huang X
    Br J Haematol; 2017 Nov; 179(4):598-605. PubMed ID: 29076142
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-CD19 chimeric antigen receptor T-cell therapy in acute lymphocytic leukaemia: a systematic review and meta-analysis.
    Anagnostou T; Riaz IB; Hashmi SK; Murad MH; Kenderian SS
    Lancet Haematol; 2020 Nov; 7(11):e816-e826. PubMed ID: 33091355
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel generation 1928zT2 CAR T cells induce remission in extramedullary relapse of acute lymphoblastic leukemia.
    Weng J; Lai P; Qin L; Lai Y; Jiang Z; Luo C; Huang X; Wu S; Shao D; Deng C; Huang L; Lu Z; Zhou M; Zeng L; Chen D; Wang Y; Chen X; Geng S; Robert W; Tang Z; He C; Li P; Du X
    J Hematol Oncol; 2018 Feb; 11(1):25. PubMed ID: 29458388
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.